Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Natera Inc (NTRA)

Natera Inc (NTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Healthcare Stocks to Target This Week

3 Healthcare Stocks to Target This Week

NTRA : 205.22 (+3.58%)
GMED : 87.81 (+0.82%)
RMD : 252.93 (+0.02%)
Natera (NTRA) Stock Trades Up, Here Is Why

Natera (NTRA) Stock Trades Up, Here Is Why

NTRA : 205.22 (+3.58%)
Why Natera (NTRA) Shares Are Falling Today

Why Natera (NTRA) Shares Are Falling Today

NTRA : 205.22 (+3.58%)
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

11 scientific abstracts, including 4 oral presentations and a concurrent publication in Nature Medicine, underscore how Signatera MRD can improve quality of life for patients with genitourinary cancers...

NTRA : 205.22 (+3.58%)
Natera: Q4 Earnings Snapshot

Natera: Q4 Earnings Snapshot

NTRA : 205.22 (+3.58%)
Natera Reports Fourth Quarter and Full Year 2025 Financial Results

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025. ...

NTRA : 205.22 (+3.58%)
Natera Earnings: What To Look For From NTRA

Natera Earnings: What To Look For From NTRA

NTRA : 205.22 (+3.58%)
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

Interventional trial validates adaptive Signatera-guided treatment approach, achieving strong 63% response rate while reducing chemotherapy exposure in 74% of patients ...

NTRA : 205.22 (+3.58%)
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2025, after the market...

NTRA : 205.22 (+3.58%)
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Large prospective study to evaluate a non-invasive prenatal screening test

NTRA : 205.22 (+3.58%)

Barchart Exclusives

2 High-Yield Dividend Stocks to Buy Now Amid the U.S.-Iran War
J.P. Morgan’s more bullish stance on select European majors makes sense here, because Eni and TotalEnergies combine mid‑single‑digit yields, below‑sector valuation multiples, and diversified upstream, downstream, and renewables portfolios that can monetize a sustained Middle East risk premium while still paying investors to wait. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar